Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Glaukos Corp (NY: GKOS )

100.93 -0.17 (-0.17%)
Official Closing Price Updated: 7:00 PM EDT, Apr 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 521,714
Open 101.24
Bid (Size) 66.00 (1)
Ask (Size) 105.00 (3)
Prev. Close 101.10
Today's Range 100.75 - 103.66
52wk Range 45.38 - 103.66
Shares Outstanding 49,470,423
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Glaukos Announces the Release of its 2023 Sustainability Report
From Glaukos Corporation
Via Business Wire
Glaukos to Release First Quarter 2024 Financial Results after Market Close on May 1
From Glaukos Corporation
Via Business Wire

Performance

YTD
+30.94%
+30.94%
1 Month
+13.76%
+13.76%
3 Month
+9.67%
+9.67%
6 Month
+54.59%
+54.59%
1 Year
+112.80%
+112.80%

More News

Read More
Analyst Ratings For Glaukos
Via Benzinga
Signet Jewelers, Dave & Buster's Entertainment, Blue Owl Capital And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Topics Stocks
Exposures US Equities
5 Analysts Have This To Say About Glaukos
Via Benzinga
Glaukos: Q4 Earnings Insights
Via Benzinga
Glaukos Receives Permanent J-code for iDose® TR (travoprost intracameral implant)
From Glaukos Corporation
Via Business Wire
Glaukos To Present Numerous Scientific Abstracts at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting
From Glaukos Corporation
Via Business Wire
Analog Devices To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
Earnings Scheduled For February 21, 2024
Via Benzinga
Analyst Ratings For Glaukos
Via Benzinga
Unveiling 7 Analyst Insights On Glaukos
Via Benzinga
Analyst Ratings for Glaukos
Via Benzinga
Glaukos Announces Fourth Quarter and Full Year 2023 Financial Results
From Glaukos Corporation
Via Business Wire
Glaukos to Release Fourth Quarter and Full Year 2023 Financial Results after Market Close on February 21
From Glaukos Corporation
Via Business Wire
Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2023 Net Sales and Reaffirms 2024 Revenue Guidance
From Glaukos Corporation
Via Business Wire
Glaukos' Newly Approved Glaucoma Treatment Is The 'Biggest Driver To Watch': Analyst
Via Benzinga
4 Analysts Have This to Say About Glaukos
Via Benzinga
Amazon.com To Rally Over 38%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
Glaukos Announces Participation in the J.P. Morgan Healthcare Conference
From Glaukos Corporation
Via Business Wire
iDoseTR Approval Sets Stage for Glaukos' Game-Changing Product, Surpassing Market Expectations, Says Analyst
Via Benzinga
Exposures Product Safety
Dow Extends Rally As Treasury Yields Tank
Via Talk Markets
Topics Economy Stocks
Exposures Interest Rates US Equities
FDA Approves Glaukos' Eye Implant To Treat Eye Pressure In Glaucoma Patients
Via Benzinga
Exposures Product Safety
Glaukos Announces FDA Approval of iDose® TR (travoprost intracameral implant)
From Glaukos Corporation
Via Business Wire
Glaukos Announces Participation in Stifel Healthcare Conference
From Glaukos Corporation
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.